Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Splenic function after splenic artery embolisation and need for vaccination
NL-OMON39016Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label trial of ProDiax-23 in splenic injury (3 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Antibody response to pneumococcal polysaccharide antigens and Howell-Jolly bodies in peripheral blood. Started Aug 2013; status: active, not recruiting.
02
Drugs
ProDiax-23
03
Conditions
splenic injury
Beyond the preview
Go deeper on NL-OMON39016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39016.